Last updated: 11/07/2018 19:16:34
A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/250mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/500mcg st ...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/250mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/500mcg st ...
Trial description: A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/250mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/500mcg st ...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Benefits of fluticasone propionates/salmeterol hfa mdi are apparent on the first day of dosing. O'Brien, J, Carlos-Palma, A, Bogolubov, M, Davies, P, and Payne, E American Lung Association/American Thoracic Society 97th International Conference 5/18/2001 San Francisco CA
Abstract: Clinical equivalence of salmeterol/fluticasone propionate combination 5/500 bid delivered via metered dose inhaler (mdi) or diskus in patients with reversible airways obstruction. van Noord, J A MD, Lill, H MD, Carillo, T MD, and Davies, P MD American Lung Association/American Thoracic Society 96th International Conference 5/5/2000
Abstract: Clinical equivalence of salmeterol/fluticasone propionate combination product (seretide) 50/500mcg bd delivered via diskus or cfc-free metred dose inhaler (mdi) in patients with reversible airways obstruction. Davies, P, Van Noord, J A, Lill, H, Carillo, T, and Greefhorst, A P 19th Congress of the European Academy of Allergology and Clinical Immunology (EAACI) 7/1/2000 Lisbon Portugal
Abstract: Comparative effectiveness of salmeterol/fluticasone propionate combination 50/500 bid delivered via metered dose inhaler or diskus in patients with reversible airways obstruction. van Noord, J A MD, Carillo, T MD, Lill, H MD, and Davies, P MD American Academy of Allergy, Asthma and Immunology 56th Annual Meeting 3/3/2000 San Diego CA
Davies P, van Noord JA, Lill H, Carrillo T, Greefhorst AP. Clinical equivalence of salmeterol/fluticasone propionate combination product (Seretide/Advair) 50/500 mcg bd delivered via Diskus or CFC-free metered dose inhaler (MDI) in patients with reversible airways obstruction. Eur J Allergy & Clin Immunol; 2000; 55 (Suppl 63): 16
O’Brien J, Carlos-Palma A, Bogolubov M, Davies P, Payne E. Benefits of fluticasone propionate/salmeterol (Advair/Seretide/Advair) HFA MDI are apparent on the first day of dosing. Am J Respir Crit Care Med 2001; 163 (5 part 2): A864
van Noord JA, Lill H, Carillo T, Davies P. Comparative effectiveness of salmeterol/fluticasone propionate combination 50/500 bid delivered via metered dose inhaler or Diskus in patients with reversible airways obstruction. J Allergy Clin Immunol 2000; 105 (1 part 2): S15 (45)
van Noord JA, Lill H, Carrillo Diaz T, Greefhorst AP, Davies P. Clinical equivalence of salmeterol/fluticasone propionate combination product (50/500?g) delivered via a chlorofluorocarbon-free metered dose inhaler with the Diskus in patients with moderate to severe asthma. Clin Drug Invest 2001: 21 (4): 243-255
van Noord JA, Lill H, Carrillo T, Davies P. Clinical equivalence of salmeterol/fluticasone propionate combination 50/500 bid delivered via metered dose inhaler (MDI) or Diskus in patients with reversible airways obstruction. Am J Respir Crit Care Med 2000; 161 (3 part 2 Suppl 1): A197
Medical condition
Airway Obstruction
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
December 1997 to March 1999
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-16-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website